Michael A Jakupec

List of Publications by Year
in descending order

189	12,709	24978	27345
papers	citations	57 h-index	106 g-index

196	196	196	8581
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Systematic Study on the Cytotoxic Potency of Commonly Used Dimeric Metal Precursors in Human Cancer Cell Lines. ChemistryOpen, 2022, 11, e202200019.	0.9	6
2	Nano-scale imaging of dual stable isotope labeled oxaliplatin in human colon cancer cells reveals the nucleolus as a putative node for therapeutic effect. Nanoscale Advances, 2021, 3, 249-262.	2.2	14
3	Highly Aromatic Flavan-3-ol Derivatives from Palaeotropical Artocarpus lacucha Buch.-Ham Possess Radical Scavenging and Antiproliferative Properties. Molecules, 2021, 26, 1078.	1.7	4
4	Tridentate 3-Substituted Naphthoquinone Ruthenium Arene Complexes: Synthesis, Characterization, Aqueous Behavior, and Theoretical and Biological Studies. Inorganic Chemistry, 2021, 60, 9805-9819.	1.9	9
5	Morphoâ€metabotyping the oxidative stress response. Scientific Reports, 2021, 11, 15471.	1.6	13
6	Thermodynamic Genome-Scale Metabolic Modeling of Metallodrug Resistance in Colorectal Cancer. Cancers, 2021, 13, 4130.	1.7	5
7	Water-soluble trithiolato-bridged dinuclear ruthenium(II) and osmium(II) arene complexes with bisphosphonate functionalized ligands as anticancer organometallics. Journal of Inorganic Biochemistry, 2021, 225, 111618.	1.5	1
8	Multifunctional Pt(<scp>iv</scp>) prodrug candidates featuring the carboplatin core and deferoxamine. Dalton Transactions, 2021, 50, 8167-8178.	1.6	9
9	KP772 overcomes multiple drug resistance in malignant lymphoma and leukemia cells in vitro by inducing Bcl-2-independent apoptosis and upregulation of Harakiri. Journal of Biological Inorganic Chemistry, 2021, 26, 897-907.	1.1	3
10	The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivoâ€”A Comparison of O,O â€, S,O â€, and N , Nâ€•Chelate Effects. Chemistry - A European Journal, 2020, 26, 2211-2221.	1.7	8
11	Naphthoquinones of natural origin: Aqueous chemistry and coordination to half-sandwich organometallic cations. Journal of Organometallic Chemistry, 2020, 907, 121070.	0.8	6
12	First insights into the novel class of organometallic compounds bearing a bidentate selenopyridone coordination motif: Synthesis, characterization, stability and biological investigations. Inorganica Chimica Acta, 2020, 513, 119919.	1.2	6
13	IntroducingN-,P-, andS-donor leaving groups: an investigation of the chemical and biological properties of ruthenium, rhodium and iridium thiopyridone piano stool complexes. Dalton Transactions, 2020, 49, 15693-15711.	1.6	10
14	Biological evaluation of novel thiomaltol-based organometallic complexes as topoisomerase IIÎ± inhibitors. Journal of Biological Inorganic Chemistry, 2020, 25, 451-465.	1.1	16
15	Tetra-(p-tolyl)antimony(III)-Containing Heteropolytungstates, [{(p-tolyl)Sb^{III}}₄(A-Î±-XW₉O₃₄)₂]^{nâ^'} (X = P, As, or Ge): Synthesis, Structure, and Study of Antibacterial and Antitumor Activity. Inorganic Chemistry, 2020, 59, 2978-2987.	1.9	15
16	Novel phthiocol-based organometallics with tridentate coordination motif and their unexpected cytotoxic behaviour. Dalton Transactions, 2020, 49, 1393-1397.	1.6	8
17	Synthesis, Modification, and Biological Evaluation of a Library of Novel Waterâ€Soluble Thiopyridoneâ€Based Organometallic Complexes and Their Unexpected (Biological) Behavior. Chemistry - A European Journal, 2020, 26, 5419-5433.	1.7	10
18	Investigations on the Anticancer Potential of Benzothiazole-Based Metallacycles. Frontiers in Chemistry, 2020, 8, 209.	1.8	10

#	Article	IF	Citations
19	Plecstatin-1 induces an immunogenic cell death signature in colorectal tumour spheroids. Metallomics, 2020, 12, 2121-2133.	1.0	27
20	Fine-Tuning the Activation Mode of an 1,3-Indandione-Based Ruthenium(II)-Cymene Half-Sandwich Complex by Variation of Its Leaving Group. Molecules, 2019, 24, 2373.	1.7	7
21	Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics. Metallomics, 2019, 11, 1716-1728.	1.0	21
22	Synthesis, Characterization, Cytotoxicity, and Time-Dependent NMR Spectroscopic Studies of (SP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Journal of Inorganic Chemistry, 2019, 2019, 856-864.	1.0	3
23	Heart-cut 2DSEC-RP-LC-ICP-MS as a screening tool in metal-based anticancer research. Journal of Analytical Atomic Spectrometry, 2019, 34, 1279-1286.	1.6	5
24	Synthesis, characterization, lipophilicity and cytotoxic properties of novel bis(carboxylato)oxalatobis(1-propylamine)platinum(IV) complexes. Inorganica Chimica Acta, 2019, 491, 76-83.	1.2	3
25	First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro. Metallomics, 2019, 11, 1044-1048.	1.0	92
26	Synthesis, characterization, cytotoxic activity, and 19F NMR spectroscopic investigations of (OC-6-33)-diacetato(ethane-1,2-diamine)bis(3,3,3-trifluoropropanoato)platinum(IV) and its platinum(II) counterpart. Inorganica Chimica Acta, 2019, 490, 190-199.	1.2	6
27	Single Spheroid Metabolomics: Optimizing Sample Preparation of Three-Dimensional Multicellular Tumor Spheroids. Metabolites, 2019, 9, 304.	1.3	16
28	N- and S-donor leaving groups in triazole-based ruthena(<scp>ii</scp>)cycles: potent anticancer activity, selective activation, and mode of action studies. Dalton Transactions, 2018, 47, 4625-4638.	1.6	18
29	Design, synthesis, nuclear localization, and biological activity of a fluorescent duocarmycin analog, HxTfA. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1342-1347.	1.0	5
30	Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action. Inorganic Chemistry, 2018, 57, 2851-2864.	1.9	45
31	The Impact of Leaving Group Variation on the Anticancer Activity of Molybdenocenes. Organometallics, 2018, 37, 3909-3916.	1.1	8
32	{Ru(CO)_x}-Core complexes with benzimidazole ligands: synthesis, X-ray structure and evaluation of anticancer activity in vivo. Dalton Transactions, 2017, 46, 3025-3040.	1.6	27
33	Comparative studies of oxaliplatin-based platinum(<scp>iv</scp>) complexes in different in vitro and in vivo tumor models. Metallomics, 2017, 9, 309-322.	1.0	60
34	Impact of the equatorial coordination sphere on the rate of reduction, lipophilicity and cytotoxic activity of platinum(IV) complexes. Journal of Inorganic Biochemistry, 2017, 174, 119-129.	1.5	25
35	Post-digestion stabilization of osmium enables quantification by ICP-MS in cell culture and tissue. Analyst, The, 2017, 142, 2327-2332.	1.7	17
36	An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin. Angewandte Chemie - International Edition, 2017, 56, 8267-8271.	7.2	97

#	Article	IF	Citations
37	Amidoxime platinum(<scp>ii</scp>) complexes: pH-dependent highly selective generation and cytotoxic activity. New Journal of Chemistry, 2017, 41, 6840-6848.	1.4	11
38	Functionalization of Ruthenium(II)(Î·⁶â€“pâ€“cymene)(3â€“hydroxyâ€“2â€“pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies. ChemPlusChem, 2017, 82, 841-847.	1.3	13
39	Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates. Inorganic Chemistry, 2017, 56, 528-541.	1.9	52
40	Platinum(IV) Complexes Featuring Axial Michael Acceptor Ligands - Synthesis, Characterization, and Cytotoxicity. European Journal of Inorganic Chemistry, 2017, 2017, 4049-4054.	1.0	12
41	Synthesis and in vivo anticancer evaluation of poly(organo)phosphazene-based metallodrug conjugates. Dalton Transactions, 2017, 46, 12114-12124.	1.6	32
42	Antiproliferative Copper(II) and Platinum(II) Complexes with Bidentate N,Nâ€Donor Ligands. European Journal of Inorganic Chemistry, 2017, 2017, 3115-3124.	1.0	13
43	InnenrÃ¼cktitelbild: Ein Organoruthenâ€Tumortherapeutikum mit unerwartet hoher SelektivitÃt fÃ¼r Plectin (Angew. Chem. 28/2017). Angewandte Chemie, 2017, 129, 8415-8415.	1.6	0
44	Ein Organoruthenâ€Tumortherapeutikum mit unerwartet hoher SelektivitÃt fÃ¼r Plectin. Angewandte Chemie, 2017, 129, 8379-8383.	1.6	14
45	Comparative equilibrium and structural studies of new pentamethylcyclopentadienyl rhodium complexes bearing (O,N) donor bidentate ligands. Journal of Organometallic Chemistry, 2017, 846, 287-295.	0.8	10
46	Lowâ€Generation Polyamidoamine Dendrimers as Drug Carriers for Platinum(IV) Complexes. European Journal of Inorganic Chemistry, 2017, 2017, 1713-1720.	1.0	20
47	Molecular mode of action of NKP-1339 â€“ a clinically investigated ruthenium-based drug â€“ involves ER- and ROS-related effects in colon carcinoma cell lines. Investigational New Drugs, 2016, 34, 261-268.	1.2	96
48	Towards targeting anticancer drugs: ruthenium(<scp>ii</scp>)â€“arene complexes with biologically active naphthoquinone-derived ligand systems. Dalton Transactions, 2016, 45, 13091-13103.	1.6	45
49	Thiomaltolâ€Based Organometallic Complexes with 1â€Methylimidazole as Leaving Group: Synthesis, Stability, and Biological Behavior. Chemistry - A European Journal, 2016, 22, 17269-17281.	1.7	32
50	Flavonoidâ€Based Organometallics with Different Metal Centers â€“ Investigations of the Effects on Reactivity and Cytotoxicity. European Journal of Inorganic Chemistry, 2016, 2016, 240-246.	1.0	21
51	The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs. Journal of Inorganic Biochemistry, 2016, 160, 264-274.	1.5	40
52	Behavior of platinum(<scp>iv</scp>) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation. Metallomics, 2016, 8, 422-433.	1.0	39
53	LA-ICP-MS imaging in multicellular tumor spheroids â€“ a novel tool in the preclinical development of metal-based anticancer drugs. Metallomics, 2016, 8, 398-402.	1.0	38
54	Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles. Journal of Biological Inorganic Chemistry, 2016, 21, 347-356.	1.1	25

#	Article	IF	Citations
55	Cytotoxicity and preliminary mode of action studies of novel 2-aryl-4-thiopyrone-based organometallics. Dalton Transactions, 2016, 45, 724-733.	1.6	20
56	Expanding on the Structural Diversity of Flavone- Derived RutheniumII(Æž6-arene) Anticancer Agents. Metallodrugs, 2015, 1, .	1.7	15
57	Bisâ€•and Tetrakis(carboxylato)platinum(IV) Complexes with Mixed Axial Ligands â€“ Synthesis, Characterization, and Cytotoxicity. Chemistry and Biodiversity, 2015, 12, 559-574.	1.0	7
58	1,3-Dioxoindan-2-carboxamides as Bioactive Ligand Scaffolds for the Development of Novel Organometallic Anticancer Drugs. Organometallics, 2015, 34, 848-857.	1.1	25
59	Solution equilibria and antitumor activities of pentamethylcyclopentadienyl rhodium complexes of picolinic acid and deferiprone. Journal of Coordination Chemistry, 2015, 68, 1583-1601.	0.8	22
60	Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs. Investigational New Drugs, 2015, 33, 835-847.	1.2	44
61	Influence of reducing agents on the cytotoxic activity of platinum(iv) complexes: induction of G2/M arrest, apoptosis and oxidative stress in A2780 and cisplatin resistant A2780cis cell lines. Metallomics, 2015, 7, 1078-1090.	1.0	34
62	Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action. Chemical Science, 2015, 6, 2449-2456.	3.7	127
63	Bis- and Tris(carboxylato)platinum(IV) Complexes with Mixed Am(m)ine Ligands in thetransPosition Exhibiting Exceptionally High Cytotoxicity. European Journal of Inorganic Chemistry, 2015, 2015, 1700-1708.	1.0	6
64	Complexes of N-hydroxyethyl-N-benzimidazolylmethylethylenediaminediacetic acid with group 12 metals and vanadiumâ€”Synthesis, structure and bioactivity of the vanadium complex. Journal of Inorganic Biochemistry, 2015, 147, 147-152.	1.5	15
65	The rearrangement of tosylated flavones to 1â€²-(alkylamino)aurones with primary amines. Tetrahedron, 2015, 71, 8953-8959.	1.0	12
66	Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups â€” A rational approach toward exploiting the platinum(IV) prodrug strategy. Journal of Inorganic Biochemistry, 2015, 153, 259-271.	1.5	24
67	Organometallic complexes of (thio)allomaltol-based Mannich-products: Synthesis, stability and preliminary biological investigations. Journal of Organometallic Chemistry, 2015, 782, 69-76.	0.8	15
68	Platinum(IV) Complexes Featuring One or Two Axial Ferrocene Bearing Ligands â€“ Synthesis, Characterization, and Cytotoxicity. European Journal of Inorganic Chemistry, 2014, 2014, 484-492.	1.0	28
69	Triapine and a More Potent Dimethyl Derivative Induce Endoplasmic Reticulum Stress in Cancer Cells. Molecular Pharmacology, 2014, 85, 451-459.	1.0	35
70	Guanidine platinum(II) complexes: synthesis, in vitro antitumor activity, and DNA interactions. Journal of Inorganic Biochemistry, 2014, 133, 33-39.	1.5	32
71	NanoSIMS combined with fluorescence microscopy as a tool for subcellular imaging of isotopically labeled platinum-based anticancer drugs. Chemical Science, 2014, 5, 3135-3143.	3.7	87
72	Ruthenium-Nitrosyl Complexes with Glycine, l-Alanine, l-Valine, l-Proline, d-Proline, l-Serine, l-Threonine, and l-Tyrosine: Synthesis, X-ray Diffraction Structures, Spectroscopic and Electrochemical Properties, and Antiproliferative Activity. Inorganic Chemistry, 2014, 53, 2718-2729.	1.9	35

#	Article	IF	Citations
73	A Novel Class of Bis- and Tris-Chelate Diam(m)inebis(dicarboxylato)platinum(IV) Complexes as Potential Anticancer Prodrugs. Journal of Medicinal Chemistry, 2014, 57, 6751-6764.	2.9	49
74	NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chemical Science, 2014, 5, 2925-2932.	3.7	552
75	Antitumor pentamethylcyclopentadienyl rhodium complexes of maltol and allomaltol: Synthesis, solution speciation and bioactivity. Journal of Inorganic Biochemistry, 2014, 134, 57-65.	1.5	73
76	Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent. Dalton Transactions, 2014, 43, 9851.	1.6	7
77	{Ru(CO)x}-core complexes with selected azoles: Synthesis, X-ray structure, spectroscopy, DFT analysis and evaluation of cytotoxic activity against human cancer cells. Polyhedron, 2014, 81, 227-237.	1.0	24
78	Dicopper(II) and Dizinc(II) Complexes with Nonsymmetric Dinucleating Ligands Based on Indolo[3,2-c]quinolines: Synthesis, Structure, Cytotoxicity, and Intracellular Distribution. Inorganic Chemistry, 2013, 52, 10137-10146.	1.9	22
79	Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes. Journal of Biological Inorganic Chemistry, 2013, 18, 249-260.	1.1	16
80	Identification of the Structural Determinants for Anticancer Activity of a Ruthenium Arene Peptide Conjugate. Chemistry - A European Journal, 2013, 19, 9297-9307.	1.7	58
81	A highly cytotoxic modified paullone ligand bearing a TEMPO free-radical unit and its copper(ii) complex as potential hR2 RNR inhibitors. Chemical Communications, 2013, 49, 10007.	2.2	18
82	X-ray Absorption Near Edge Structure Spectroscopy to Resolve the in Vivo Chemistry of the Redox-Active Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019). Journal of Medicinal Chemistry, 2013, 56, 1182-1196.	2.9	49
83	Novel metal(ii) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agents. Chemical Science, 2013, 4, 1837.	3.7	111
84	3-Hydroxyflavones vs. 3-hydroxyquinolinones: structureâ€“activity relationships and stability studies on Ru^{II}(arene) anticancer complexes with biologically active ligands. Dalton Transactions, 2013, 42, 6193-6202.	1.6	74
85	Theoretical Investigations and Density Functional Theory Based Quantitative Structureâ€“Activity Relationships Model for Novel Cytotoxic Platinum(IV) Complexes. Journal of Medicinal Chemistry, 2013, 56, 330-344.	2.9	76
86	Striking Difference in Antiproliferative Activity of Ruthenium- and Osmium-Nitrosyl Complexes with Azole Heterocycles. Inorganic Chemistry, 2013, 52, 6273-6285.	1.9	39
87	Bulky N,N-(Di)alkylethane-1,2-diamineplatinum(II) Compounds as Precursors for Generating Unsymmetrically Substituted Platinum(IV) Complexes. Inorganic Chemistry, 2013, 52, 8151-8162.	1.9	32
88	Osmiumâ€Nitrosyl Complexes with Glycine, Picolinic Acid, Â<scp>L</scp>â€Proline and <scp>D</scp>â€Proline: Synthesis, Structures and Antiproliferative Activity. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2013, 639, 1590-1597.	0.6	8
89	Metalâ€“Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation. Organometallics, 2013, 32, 903-914.	1.1	57
90	Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity. Chemical Communications, 2013, 49, 3348.	2.2	127

#	Article	IF	Citations
91	Am(m)ines Make the Difference: Organoruthenium Am(m)ine Complexes and Their Chemistry in Anticancer Drug Development. Chemistry - A European Journal, 2013, 19, 4308-4318.	1.7	31
92	Influence of the Ï€-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes. Frontiers in Chemistry, 2013, 1, 27.	1.8	23
93	Waterâ€Soluble Cationic Derivatives of Indirubin, the Active Anticancer Component from Indigo naturalis. Chemistry and Biodiversity, 2012, 9, 2175-2185.	1.0	5
94	Novel Oximato-Bridged Platinum(II) Di- and Trimer(s): Synthetic, Structural, and in Vitro Anticancer Activity Studies. Inorganic Chemistry, 2012, 51, 7153-7163.	1.9	22
95	Ruthenium- and osmium-arene complexes of 8-substituted indolo[3,2-c]quinolines: Synthesis, X-ray diffraction structures, spectroscopic properties, and antiproliferative activity. Inorganica Chimica Acta, 2012, 393, 252-260.	1.2	20
96	Solid-phase synthesis of oxaliplatinâ€“TATpeptide bioconjugates. Dalton Transactions, 2012, 41, 3001-3005.	1.6	65
97	Osmium(IV) complexes with 1H- and 2H-indazoles: Tautomer identity versus spectroscopic properties and antiproliferative activity. Journal of Inorganic Biochemistry, 2012, 113, 47-54.	1.5	38
98	A SAR Study of Novel Antiproliferative Ruthenium and Osmium Complexes with Quinoxalinone Ligands in Human Cancer Cell Lines. Journal of Medicinal Chemistry, 2012, 55, 3398-3413.	2.9	98
99	Diamminetetrakis(carboxylato)platinum(IV) Complexes â€“ Synthesis, Characterization, and Cytotoxicity. Chemistry and Biodiversity, 2012, 9, 1840-1848.	1.0	11
100	Ruthenium- and osmium-arene-based paullones bearing a TEMPO free-radical unit as potential anticancer drugs. Chemical Communications, 2012, 48, 8559.	2.2	40
101	X-ray Absorption Spectroscopy of an Investigational Anticancer Gallium(III) Drug: Interaction with Serum Proteins, Elemental Distribution Pattern, and Coordination of the Compound in Tissue. Journal of Medicinal Chemistry, 2012, 55, 5601-5613.	2.9	36
102	Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder. Chemical Communications, 2012, 48, 4839.	2.2	130
103	Unsymmetric Mono- and Dinuclear Platinum(IV) Complexes Featuring an Ethylene Glycol Moiety: Synthesis, Characterization, and Biological Activity. Journal of Medicinal Chemistry, 2012, 55, 11052-11061.	2.9	34
104	Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells. Journal of Inorganic Biochemistry, 2012, 116, 180-187.	1.5	59
105	<scp>l</scp>- and <scp>d</scp>-Proline Thiosemicarbazone Conjugates: Coordination Behavior in Solution and the Effect of Copper(II) Coordination on Their Antiproliferative Activity. Inorganic Chemistry, 2012, 51, 9309-9321.	1.9	64
106	Novel tetracarboxylatoplatinum(<scp>iv</scp>) complexes as carboplatin prodrugs. Dalton Transactions, 2012, 41, 14404-14415.	1.6	76
107	Structureâ€“Activity Relationships of Targeted Ru^{II}(Î·⁶-p-Cymene) Anticancer Complexes with Flavonol-Derived Ligands. Journal of Medicinal Chemistry, 2012, 55, 10512-10522.	2.9	132
108	Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs. Molecular Pharmacology, 2012, 81, 719-728.	1.0	54

#	Article	IF	Citations
109	Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules. Chemical Communications, 2012, 48, 1475-1477.	2.2	91
110	Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds. Journal of Biological Inorganic Chemistry, 2012, 17, 465-474.	1.1	51
111	Organometallic 3-(1H-Benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines as Potential Anticancer Agents. Inorganic Chemistry, 2011, 50, 11715-11728.	1.9	32
112	Conjugation of Organoruthenium(II) 3-(1H-Benzimidazol-2-yl)pyrazolo[3,4-b]pyridines and Indolo[3,2-d]benzazepines to Recombinant Human Serum Albumin: a Strategy To Enhance Cytotoxicity in Cancer Cells. Inorganic Chemistry, 2011, 50, 12669-12679.	1.9	56
113	Physicochemical Studies and Anticancer Potency of Ruthenium Î·⁶-p-Cymene Complexes Containing Antibacterial Quinolones. Organometallics, 2011, 30, 2506-2512.	1.1	105
114	Synthesis, Characterization, and Cytotoxic Activity of Novel Potentially pH-Sensitive Nonclassical Platinum(II) Complexes Featuring 1,3-Dihydroxyacetone Oxime Ligands. Inorganic Chemistry, 2011, 50, 10673-10681.	1.9	34
115	Rutheniumâ^' and Osmiumâ^'Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity. Organometallics, 2011, 30, 273-283.	1.1	55
116	Mono-carboxylated diaminedichloridoplatinum(<scp>iv</scp>) complexes â€“ selective synthesis, characterization, and cytotoxicity. Dalton Transactions, 2011, 40, 8187-8192.	1.6	33
117	En Route to Osmium Analogues of KP1019: Synthesis, Structure, Spectroscopic Properties and Antiproliferative Activity of trans-[Os^{IV}Cl₄(Hazole)₂]. Inorganic Chemistry, 2011, 50, 7690-7697.	1.9	49
118	Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin. European Journal of Medicinal Chemistry, 2011, 46, 5456-5464.	2.6	70
119	Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019. Journal of Biological Inorganic Chemistry, 2011, 16, 1205-1215.	1.1	23
120	Synthesis, structures and in vitro cytotoxicity of some cationic cis-platinum(II) complexes containing chelating thiocarbamates. Journal of Inorganic Biochemistry, 2011, 105, 462-466.	1.5	12
121	Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. Journal of Inorganic Biochemistry, 2011, 105, 46-51.	1.5	107
122	From hydrolytically labile to hydrolytically stable Ruâ€“arene anticancer complexes with carbohydrate-derived co-ligands. Journal of Inorganic Biochemistry, 2011, 105, 224-231.	1.5	65
123	Osmium(ii)â€“versus ruthenium(ii)â€“arene carbohydrate-based anticancer compounds: similarities and differences. Dalton Transactions, 2010, 39, 7345.	1.6	88
124	Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy. Journal of Biological Inorganic Chemistry, 2010, 15, 903-918.	1.1	51
125	New platinumâ€“oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro. Journal of Inorganic Biochemistry, 2010, 104, 799-814.	1.5	50
126	Is the Reactivity of M(II)â^'Arene Complexes of 3-Hydroxy-2(1H)-pyridones to Biomolecules the Anticancer Activity Determining Parameter?. Inorganic Chemistry, 2010, 49, 7953-7963.	1.9	101

#	Article	IF	Citations
127	{(1R,2R,4R)-4-Methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): A Novel Enantiomerically Pure Oxaliplatin Derivative Showing Improved Anticancer Activity in Vivo. Journal of Medicinal Chemistry, 2010, 53, 7356-7364.	2.9	51
128	Highly Cytotoxic Copper(II) Complexes with Modified Paullone Ligands. Inorganic Chemistry, 2010, 49, 302-311.	1.9	48
129	Influence of the Arene Ligand and the Leaving Group on the Anticancer Activity of (Thio)maltol Ruthenium(II)â€“(Î·6-Arene) Complexes. Australian Journal of Chemistry, 2010, 63, 1521.	0.5	33
130	Novel Cis- and Trans-Configured Bis(oxime)platinum(II) Complexes: Synthesis, Characterization, and Cytotoxic Activity. Inorganic Chemistry, 2010, 49, 5669-5678.	1.9	49
131	Structureâ^'Activity Relationships of Highly Cytotoxic Copper(II) Complexes with Modified Indolo[3,2-c]quinoline Ligands. Inorganic Chemistry, 2010, 49, 11084-11095.	1.9	55
132	Fluorescence properties and cellular distribution of the investigational anticancer drugTriapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(ii) complex. Dalton Transactions, 2010, 39, 704-706.	1.6	77
133	The influence of electroporation on cytotoxicity of anticancer ruthenium(III) complex KP1339 in vitro and in vivo. Anticancer Research, 2010, 30, 2055-63.	0.5	14
134	Maltolâ€Derived Rutheniumâ€“Cymene Complexes with Tumor Inhibiting Properties: The Impact of Ligandâ€“Metal Bond Stability on Anticancer Activity In Vitro. Chemistry - A European Journal, 2009, 15, 12283-12291.	1.7	111
135	A Novel Cytotoxic Cerium Complex: Aquatrichloridobis(1,10â€phenanthroline)cerium(III) (KP776). Synthesis, Characterization, Behavior in H₂O, Binding towards Biomolecules, and Antiproliferative Activity. Chemistry and Biodiversity, 2009, 6, 2153-2165.	1.0	21
136	Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety. Journal of Organometallic Chemistry, 2009, 694, 922-929.	0.8	64
137	[Os^{IV}Cl₅(Hazole)]^{â^'} Complexes: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity. Inorganic Chemistry, 2009, 48, 10737-10747.	1.9	21
138	Transferring the Concept of Multinuclearity to Ruthenium Complexes for Improvement of Anticancer Activity. Journal of Medicinal Chemistry, 2009, 52, 916-925.	2.9	168
139	From Pyrone to Thiopyrone Ligandsâ^'Rendering Maltol-Derived Ruthenium(II)â^'Arene Complexes That Are Anticancer Active in Vitro. Organometallics, 2009, 28, 4249-4251.	1.1	85
140	Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation. Journal of Medicinal Chemistry, 2009, 52, 5032-5043.	2.9	143
141	Influence of the Arene Ligand, the Number and Type of Metal Centers, and the Leaving Group on thein VitroAntitumor Activity of Polynuclear Organometallic Compounds. Organometallics, 2009, 28, 6260-6265.	1.1	92
142	Synthesis and biological studies of some gold(I) complexes containing functionalised alkynes. Dalton Transactions, 2009, , 10841.	1.6	56
143	Synthesis, X-ray diffraction structure, spectroscopic properties and antiproliferative activity of a novel ruthenium complex with constitutional similarity to cisplatin. Dalton Transactions, 2009, , 3334.	1.6	27
144	Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. Journal of Analytical Atomic Spectrometry, 2009, 24, 51-61.	1.6	100

#	Article	IF	Citations
145	The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines. Melanoma Research, 2009, 19, 283-293.	0.6	56
146	In Vitro Anticancer Activity and Biologically Relevant Metabolization of Organometallic Ruthenium Complexes with Carbohydrateâ€Based Ligands. Chemistry - A European Journal, 2008, 14, 9046-9057.	1.7	111
147	Hydrolysis and Cytotoxic Properties of Osmium(II)/(III)-DMSO-Azole Complexes. Short Communication. Chemistry and Biodiversity, 2008, 5, 1588-1593.	1.0	12
148	KP1019, A New Redoxâ€Active Anticancer Agent â€“ Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients. Chemistry and Biodiversity, 2008, 5, 2140-2155.	1.0	732
149	Novel Endothallâ€Containing Platinum(IV) Complexes: Synthesis, Characterization, and Cytotoxic Activity. Chemistry and Biodiversity, 2008, 5, 2160-2170.	1.0	38
150	Synthesis, structures and in vitro cytotoxicity of some platinum(II) complexes containing thiocarbamate esters. Journal of Inorganic Biochemistry, 2008, 102, 2067-2071.	1.5	29
151	Novel bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) complexes with exceptionally high cytotoxicity. Journal of Inorganic Biochemistry, 2008, 102, 2072-2077.	1.5	41
152	Water-Soluble Mixed-Ligand Ruthenium(II) and Osmium(II) Arene Complexes with High Antiproliferative Activity. Organometallics, 2008, 27, 6587-6595.	1.1	71
153	Resistance against novel anticancer metal compounds: Differences and similarities. Drug Resistance Updates, 2008, 11, 1-16.	6.5	201
154	Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity In Vitro of Novel Osmium(III) Complexes with Azole Heterocycles. Inorganic Chemistry, 2008, 47, 7338-7347.	1.9	32
155	Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Rutheniumâ^'Arene Compounds. Organometallics, 2008, 27, 2405-2407.	1.1	180
156	Reversion of Structure-Activity Relationships of Antitumor Platinum Complexes by Acetoxime but Not Hydroxylamine Ligands. Molecular Pharmacology, 2007, 71, 357-365.	1.0	53
157	Gallium(III) and Iron(III) Complexes of Î±-N-Heterocyclic Thiosemicarbazones:â€‰ Synthesis, Characterization, Cytotoxicity, and Interaction with Ribonucleotide Reductase. Journal of Medicinal Chemistry, 2007, 50, 1254-1265.	2.9	145
158	Highly Antiproliferative Ruthenium(II) and Osmium(II) Arene Complexes with Paullone-Derived Ligands. Organometallics, 2007, 26, 6643-6652.	1.1	134
159	Novel Di- and Tetracarboxylatoplatinum(IV) Complexes. Synthesis, Characterization, Cytotoxic Activity, and DNA Platination. Journal of Medicinal Chemistry, 2007, 50, 6692-6699.	2.9	88
160	Osmium NAMI-A Analogues:Â Synthesis, Structural and Spectroscopic Characterization, and Antiproliferative Properties. Inorganic Chemistry, 2007, 46, 5023-5033.	1.9	66
161	The First Ruthenium-Based Paullones:â€‰ Syntheses, X-ray Diffraction Structures, and Spectroscopic and Antiproliferative Properties in Vitro. Inorganic Chemistry, 2007, 46, 3645-3656.	1.9	40
162	Structureâ^'Activity Relationships for NAMI-A-type Complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = Imidazole, Indazole, 1,2,4-Triazole, 4-Amino-1,2,4-triazole, and 1-Methyl-1,2,4-triazole):Â Aquation, Redox Properties, Protein Binding, and Antiproliferative Activity. Journal of Medicinal Chemistry, 2007, 50, 2185-2193.	2.9	206

#	Article	IF	Citations
163	Metal-Based Paullones as Putative CDK Inhibitors for Antitumor Chemotherapy. Journal of Medicinal Chemistry, 2007, 50, 6343-6355.	2.9	86
164	Ruthenium(II) Complexes of Thiosemicarbazones: The First Water-Soluble Complex with pH-Dependent Antiproliferative Activity. European Journal of Inorganic Chemistry, 2007, 2007, 2870-2878.	1.0	43
165	A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin?. ChemMedChem, 2007, 2, 505-514.	1.6	49
166	Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones. Journal of Inorganic Biochemistry, 2007, 101, 1946-1957.	1.5	71
167	Antitumour metal compounds: more than theme and variations. Dalton Transactions, 2007, , 183-194.	1.6	767
168	Redox behavior of tumor-inhibiting ruthenium(iii) complexes and effects of physiological reductants on their binding to GMP. Dalton Transactions, 2006, , 1796.	1.6	197
169	The First Metal-Based Paullone Derivative with High Antiproliferative Activity in Vitro. Inorganic Chemistry, 2006, 45, 1945-1950.	1.9	46
170	From bench to bedside â€“ preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). Journal of Inorganic Biochemistry, 2006, 100, 891-904.	1.5	882
171	Preclinical characterization of anticancer gallium(III) complexes: Solubility, stability, lipophilicity and binding to serum proteins. Journal of Inorganic Biochemistry, 2006, 100, 1819-1826.	1.5	100
172	Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochemical Pharmacology, 2006, 71, 426-440.	2.0	124
173	Synthesis, Cytotoxicity, and Structure-Activity Relationships of New Oxaliplatin Derivatives. Monatshefte FÃ¼r Chemie, 2005, 136, 693-700.	0.9	16
174	Synthesis andin vitroAntitumor Potency of (Cyclohexane-1,2-Diamine)Platinum(II) Complexes with Aminotris(Methylenephosphonic Acid) as Bone-Seeking Ligand. Bioinorganic Chemistry and Applications, 2005, 3, 179-190.	1.8	8
175	Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches. Current Medicinal Chemistry, 2005, 12, 2075-2094.	1.2	657
176	Redox-Active Antineoplastic Ruthenium Complexes with Indazole:Â Correlation of in Vitro Potency and Reduction Potential. Journal of Medicinal Chemistry, 2005, 48, 2831-2837.	2.9	156
177	The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Letters, 2005, 226, 115-121.	3.2	111
178	Gallium in Cancer Treatment. Current Topics in Medicinal Chemistry, 2004, 4, 1575-1583.	1.0	138
179	Synthesis, crystal structure and pH dependent cytotoxicity of (SP-4-2)-bis(2-aminoethanolato-Î²2N,O)platinum(II) â€“ a representative of novel pH sensitive anticancer platinum complexes. Inorganica Chimica Acta, 2004, 357, 3237-3244.	1.2	46
180	Synthesis, crystal structure and cytotoxicity of new oxaliplatin analogues indicating that improvement of anticancer activity is still possible. European Journal of Medicinal Chemistry, 2004, 39, 707-714.	2.6	51

#	Article	IF	Citations
181	Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy. Journal of Analytical Atomic Spectrometry, 2004, 19, 46.	1.6	183
182	Gallium and Other Main Group Metal Compounds as Antitumor Agents. , 2004, , 425-462.		45
183	The Effect of Cytoprotective Agents in Platinum Anticancer Therapy. , 2004, , 179-208.		8
184	The effect of cytoprotective agents in platinum anticancer therapy. Metal Ions in Biological Systems, 2004, 42, 179-208.	0.4	2
185	Gallium and other main group metal compounds as antitumor agents. Metal Ions in Biological Systems, 2004, 42, 425-62.	0.4	12
186	Synthesis, X-ray Diffraction Structures, Spectroscopic Properties, and in vitro Antitumor Activity of Isomeric (1H-1,2,4-Triazole)Ru(III) Complexes. Inorganic Chemistry, 2003, 42, 6024-6031.	1.9	94
187	Synthesis, Characterization, and in Vitro Antitumor Activity of Osteotropic Diam(m)ineplatinum(II) Complexes Bearing aN,N-Bis(phosphonomethyl)glycine Ligandâ€. Journal of Medicinal Chemistry, 2003, 46, 4946-4951.	2.9	58
188	Novel glucose-ferrocenyl derivatives: synthesis and properties. New Journal of Chemistry, 2002, 26, 671-673.	1.4	28
189	Synthesis, structure, spectroscopic and in vitro antitumour studies of a novel gallium(III) complex with 2-acetylpyridine 4N-dimethylthiosemicarbazone. Journal of Inorganic Biochemistry, 2002, 91, 298-305.	1.5	97